OM
NBRV

Opaleye Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Opaleye Management’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-958
Closed -$1.69M – 48
2016
Q3 		$1.69M Sell
958
-122
-11% -$235K 0.88% 35
2016
Q2 		$2.02M Sell
1,080
-15
-1% -$30.2K 1.35% 29
2016
Q1 		$2.45M Buy
1,095
+215
+24% +$462K 1.53% 27
2015
Q4 		$2.12M Buy
+880
New +$2.15M 0.88% 41

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Opaleye Management's NBRV Position: Q4 2016 in Review

Opaleye Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2016, closing a stake of 958 shares — an estimated $1.69M sold.

Opaleye Management first reported a position in NBRV in Q4 2015 and held it in 4 quarters. The position peaked at $2.45M in Q1 2016. 23 funds tracked by Wall St. Rank hold NBRV as of Q4 2016.

  • Opaleye Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2016 after selling out during the quarter.
  • Opaleye Management sold 958 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2016, an estimated $1.69M.
  • Opaleye Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2015 and held it in 4 quarters.
  • Opaleye Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $2.45M in Q1 2016.
  • 23 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2016.

Based on Opaleye Management's 13F filing for Q4 2016, filed 21 Feb 2017.